Stereotaxis (STXS) 10-Q 10 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	1,289,340
Trading Symbol	stxs
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q2
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		21,853,376

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,858,089	$ 5,593,582
Accounts receivable, net of allowance of $251,933 and $93,478 in 2016 and 2015, respectively	5,057,503	6,376,470
Inventories	5,334,687	4,504,282
Prepaid expenses and other current assets	569,825	668,659
Total current assets	14,820,104	17,142,993
Property and equipment, net	857,869	1,067,321
Intangible assets, net	536,229	635,889
Other assets	44,774	31,693
Total assets	16,258,976	18,877,896
Current liabilities:
Short-term debt	3,000,000
Accounts payable	2,427,697	1,840,135
Accrued liabilities	5,431,055	6,058,390
Deferred revenue	7,435,975	7,445,935
Warrants and debt conversion features	627,466	794,130
Total current liabilities	18,922,193	16,138,590
Long-term debt	18,114,408	18,080,159
Long-term deferred revenue	620,945	2,009,198
Other liabilities	270,296	275,603
Total liabilities	37,927,842	36,503,550
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2016 and 2015
Common stock, par value $0.001; 300,000,000 shares authorized, 21,846,095 and 21,551,173, shares issued at 2016 and 2015, respectively	21,846	21,551
Additional paid in capital	449,081,382	448,517,472
Treasury stock, 4,015 shares at 2016 and 2015	(205,999)	(205,999)
Accumulated deficit	(470,566,095)	(465,958,678)
Total stockholders' deficit	(21,668,866)	(17,625,654)
Total liabilities and stockholders' deficit	$ 16,258,976	$ 18,877,896

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Accounts receivable, allowance	$ 251,933	$ 93,478
Stockholders' deficit:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	21,846,095	21,551,173
Treasury stock, shares	4,015	4,015

Statements Of Operations

Statements Of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Systems	$ 935,978	$ 3,092,935	$ 3,010,997	$ 5,924,113
Disposables, service and accessories	6,938,645	6,571,315	13,511,632	13,271,163
Total revenue	7,874,623	9,664,250	16,522,629	19,195,276
Cost of revenue:
Systems	395,898	1,849,275	1,478,996	3,249,542
Disposables, service and accessories	699,173	1,093,988	1,796,888	2,324,359
Total cost of revenue	1,095,071	2,943,263	3,275,884	5,573,901
Gross margin	6,779,552	6,720,987	13,246,745	13,621,375
Operating expenses:
Research and development	1,421,380	1,419,826	2,894,465	2,905,533
Sales and marketing	4,211,706	4,250,779	8,105,819	8,285,150
General and administrative	2,786,046	2,772,708	5,372,838	5,567,297
Total operating expenses	8,419,132	8,443,313	16,373,122	16,757,980
Operating loss	(1,639,580)	(1,722,326)	(3,126,377)	(3,136,605)
Other income	135,370	999,169	166,664	106,792
Interest income	140	493	362	1,355
Interest expense	(829,046)	(816,023)	(1,648,066)	(1,645,810)
Net loss	$ (2,333,116)	$ (1,538,687)	$ (4,607,417)	$ (4,674,268)
Net loss per common share:
Basic	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.22)
Diluted	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.22)
Weighted average shares used in computing net loss per common share:
Basic	21,793,583	21,007,103	21,702,597	20,871,244
Diluted	21,793,583	21,007,103	21,702,597	20,871,244

Statements Of Cash Flows

Statements Of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (4,607,417)	$ (4,674,268)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	185,802	134,025
Amortization of intangibles	99,660	149,917
Amortization of deferred finance costs	108,850	111,018
Share-based compensation	566,975	637,246
Adjustment of warrants	(166,664)	(106,792)
Changes in operating assets and liabilities:
Accounts receivable	1,318,967	(969,414)
Inventories	(806,755)	609,088
Prepaid expenses and other current assets	147,942	244,527
Other assets	(13,081)	67,541
Accounts payable	587,562	(60,014)
Accrued liabilities	(627,335)	497,625
Deferred revenue	(1,398,213)	(435,029)
Other liabilities	(5,307)	(409,358)
Net cash used in operating activities	(4,609,014)	(4,203,888)
Cash flows from investing activities
Purchase of equipment		(52,410)
Net cash used in investing activities		(52,410)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)
Proceeds from (payments of) revolving line of credit	3,000,000
Payments of Healthcare Royalty Partners debt	(23,709)	(80,328)
Proceeds from issuance of stock, net of issuance costs	(2,770)	695,598
Net cash provided by (used in) financing activities	2,873,521	615,270
Net increase (decrease) in cash and cash equivalents	(1,735,493)	(3,641,028)
Cash and cash equivalents at beginning of period	5,593,582	7,270,301
Cash and cash equivalents at end of period	$ 3,858,089	$ 3,629,273

Description Of Business

Description Of Business	6 Months Ended
	Jun. 30, 2016
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures, and markets the Epoch ® Solution, an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency, and efficacy for catheter-based or interventional procedures. The Epoch Solution is comprised of the Niobe ® ES Magnetic Navigation System (“ Niobe ES system”), Odyssey ® Information Management Solution (“ Odyssey Solution”), and the Vdrive ® Robotic Navigation System (“ Vdrive system”) and related devices. The Niobe ES system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures, and reduced X-ray exposure. In addition to the Niobe ES system and its components, Stereotaxis has also developed the Odyssey Solution, which consolidates all lab information, enabling doctors to focus on the patient for optimal procedure efficiency. The platform also features a remote viewing and recording capability called the Odyssey Cinema ™ system, an innovative system delivering synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital’s local area network and over the global Odyssey Network, providing physicians with a tool for clinical collaboration, remote consultation, and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system’s control of therapeutic catheters for fully remote procedures and enables single-operator workflow. It is sold as two options, the Vdrive system and the Vdrive Duo ™ system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond the warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion may be implemented upon purchase of the necessary components. As of June 30 , 2016, the Company has an installed base of 129 Niobe ES systems. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan and various other countries. We have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and European Union. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union. We have received Food and Drug Administration (“FDA”) clearance and the CE Mark necessary for us to market our suite of Pegasus ™ coronary peripheral guidewires in the United States and Europe. Since our inception, we have generated significant losses. As of June 30, 2016, we have incurred cumulative net losses of approximately $470.6 million. In 2016, the Company plans to continue developing the Niobe ES system with the goal of furthering clinical adoption and new system placements. We expect to incur additional losses in 2016 as we continue the development and commercialization of our products, conduct our researc h and development activities, advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives. During 2016, we will continue to monitor operating expenses and make additional investment s in certain targeted areas . Our existing cash, cash equivalents, and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing. We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities, and loans collateralized by working capital and equipment. We continue to explore financing alternatives, which may include the sale of equity securities or non-core assets, strategic collaboration agreements, debt financings, or distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control. We cannot assure that additional financing will be available on acceptable terms or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves, or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition, and operational results. In addition, we could be required to cease operations.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the six month period ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission (SEC) on March 11, 2016. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details. Revenue and Costs of Revenue The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Net Earnings (Loss) per Common Share (“EPS”) Basic and diluted net earnings (loss) per common share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. The following table sets forth the computation of basic and diluted EPS:    Three months ended June 30, Six months ended June 30,  Numerator: 2016 2015 2016 2015  Numerator for basic EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Numerator for diluted EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Denominator:  Denominator for basic EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Denominator for diluted EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Basic EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22)  Diluted EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22)  In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.  As of June 30, 2016, the Company had 686,383 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.66 per share, 2,040,365 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.44 per share, and 1,212,496 shares of unvested restricted share units. Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company is evaluating the impact of this guidance on its financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842)”, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We adopted this accounting standard update in 2015 and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have adopted this accounting standard update. The Company’s balance sheets as of June 30, 2016 and December 31, 2015 included $291,060 and $349,018 , respectively, of deferred financing costs (excluding $75,068 and $25,960 , respectively, related to line-of-credit arrangements) that were, under the new guidance, presented as a direct reduction to debt liabilities. In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists and when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We are currently evaluating the impact of adopting this accounting standard update on our financial statement disclosures. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. In April 2015, the FASB issued an exposure draft related to the deferral of the effective date, which would delay our effective date one year. Therefore, the standard would be effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). We are currently evaluating the impact of adopting this accounting standard update on our financial statements and disclosures and have not concluded on an adoption method.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2016
Inventories [Abstract]
Inventories	3. Inventories Inventories consist of the following:    June 30, 2016 December 31, 2015   Raw materials $ 2,476,263 $ 2,065,676  Work in process 876,105 24,758  Finished goods 2,014,872 2,433,819  Reserve for obsolescence (32,553) (19,971)  Total inventory $ 5,334,687 $ 4,504,282 

Prepaid Expenses And Other Curr

Prepaid Expenses And Other Current Assets	6 Months Ended
	Jun. 30, 2016
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:       June 30, 2016 December 31, 2015   Prepaid expenses $ 293,484 $ 454,822  Deferred financing costs 75,068 25,960  Deposits 245,650 136,583  Deferred cost of revenue 397 82,987  Total prepaid expenses and other assets 614,599 700,352  Less: Noncurrent prepaid expenses and other assets (44,774) (31,693)  Total current prepaid expenses and other assets $ 569,825 $ 668,659                Certain prior year amounts have been reclassified to conform to the 2016 presentation.

Property And Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2016
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment consist of the following:    June 30, December 31,  2016 2015   Equipment $ 8,386,835 $ 8,496,636  Equipment held for lease 303,412 303,412  Leasehold improvements 2,320,368 2,320,368  11,010,615 11,120,416  Less: Accumulated depreciation (10,152,746) (10,053,095)  Net property and equipment $ 857,869 $ 1,067,321 

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2016
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets  As of June 3 0 , 201 6 , the Company had total intangible assets of $3,221,069 . Accumulated amortization at June 3 0, 2016 , was $2,684,840 .   

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities [Abstract]
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following:    June 30, December 31,  2016 2015   Accrued salaries, bonus, and benefits $ 2,652,318 $ 3,053,012  Accrued rent 1,159,038 1,361,379  Accrued licenses and maintenance fees 575,583 666,373  Accrued interest 494,067 494,703  Accrued warranties 258,450 316,835  Accrued taxes 313,379 324,226  Other 248,516 117,465  Total accrued liabilities 5,701,351 6,333,993  Less: Long term accrued liabilities (270,296) (275,603)  Total current accrued liabilities $ 5,431,055 $ 6,058,390   Our primary company facilities are located in St. Louis, Missouri where we currently lease approximately 52,000 square feet of office and 12,000 square feet of demonstration and assembly space. In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 and were accrued as a rent liability as of September 30, 2013. As of June 3 0, 2016 , the remaining accrued costs associated with the termination were $233,197 . In the fourth quarter of 2015, the Company entered a sublease agreement to sublease 3,152 square feet of the first floor office space through December 31, 2018 . In July 2016, the Company and the subtenant mutually agreed to an early termination of the sublease, effective July 31, 2016 .

Deferred Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2016
Deferred Revenue [Abstract]
Deferred Revenue	8. Deferred Revenue Deferred revenue consists of the following:    June 30, December 31,  2016 2015   Product shipped, revenue deferred $ 338,831 $ 366,388  Customer deposits 1,050,000 2,505,000  Deferred service and license fees 6,668,089 6,583,745  Total deferred revenue 8,056,920 9,455,133  Less: Long-term deferred revenue (620,945) (2,009,198)  Total current deferred revenue $ 7,435,975 $ 7,445,935 

Long-Term Debt And Credit Facil

Long-Term Debt And Credit Facilities	6 Months Ended
	Jun. 30, 2016
Long-Term Debt And Credit Facilities [Abstract]
Long-Term Debt And Credit Facilities	9. Long-Term Debt and Credit Facilities Debt outstanding consists of the following:     June 30, 2016 December 31, 2015  Carrying Estimated Carrying Estimated  Amount Fair Value Amount Fair Value   Revolving line of credit, due March 31, 2018 $ 3,000,000 $ 3,000,000 $ - $ -  Healthcare Royalty Partners debt 18,114,408 18,405,468 18,080,159 18,429,177  Total debt 21,114,408 21,405,468 18,080,159 18,429,177  Less current maturities (3,000,000) (3,000,000) — —  Total long term debt $ 18,114,408 $ 18,405,468 $ 18,080,159 $ 18,429,177  In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measur ed at fair value as of June 3 0 , 201 6 and December 31, 201 5 . Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3). Certain prior year amounts have been reclassified to conform to the 2016 presentation.  Revolving Line of Credit The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $10.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018 and on May 10, 2016 , the Company and the primary lender agreed to modify certain financial covenants . The amended agreement requires the Company to maintain a liquidity ratio greater than 1.50 :1.00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than ( no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018. As of June 30, 2016, the Company had $3.0 million outstanding under the revolving line of credit. Draws on the line of credit are made based on the borrowing c apacity one week in arrears. As of June 30, 2016, the Company had a borrowing capacity of $4.0 million based on the Company’s collateralized assets, i ncluding amounts already drawn. As such, the Company has the ability to borrow an additional $1.0 million under the revolving li ne of credit at June 30, 2016. The Company’s total liquidity as of June 30, 2016, was $4.9 million which included cash and cash equivalents of $3.9 million. The $3.0 million outstanding under the revolving line of credit was repaid shortly after June 30, 2016 . Healthcare Royalty Partners Debt In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners. Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe ES system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the three months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. (the “Biosense Agreement”). The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe ES system in cardiac ablation procedures. Under the terms of the agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018 , and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement. Since the Company’s inception, no dividends have been declared or paid . Controlled Equity Offering The Company entered into a Controlled Equity Offering SM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company will pay Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement. There were no proceeds from the Controlled Equity Offering during the three months ended June 30, 2016. As of June 3 0 , 2016 , $13.8 million of common stock remained available to be sold under this facility, subject to certain conditions as specified in the Sales Agreement . Due to the Company’s transfer to the OTCQX® Best Market on August 4, 2016, the Company’s ability to generate proceeds from the sale of stock under the Controlled Equity Offering in the future may be limited or prohibited. Offerings of Common Stock On October 8, 2015 the Company announced the results of its previously announced offering of transferable subscription warrants (the “Warrants Offering) to holders of record of the Company’s common stock. Pursuant to the Warrants Offering, subscription warrants to purchase 267,256 shares of common stock were exercised, resulting in gross proceeds to the Company of $293,982 . Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted the 2012 S tock I ncentive P la n (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012. On June 5, 2013, June 10, 2014, and on May 24, 2016 the shareholders approved amendments to the Plan, which were previously approved and adopted by the Compensation Committee of the Board of Directors of the Company. Under each of the amendments on June 5, 2013 and June 10, 2014, the number of shares authorized for issuance under the Plan was increased by one million shares. The amendment on May 24, 2016 increased the number of shares authorized for issuance under the Plan by 1.5 million shares. At June 30, 2016 , the Company had 1,508,565 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans. At June 3 0 , 201 6 , the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.9 million , net of estimated forfeitures of approximately $0.9 million . This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods. A summary of the option and stock appreciat ion rights activity for the six month period ended June 30 , 201 6 is as follows:    Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2015 706,494 $1.45 - $116.40 $9.34  Granted 1,000 $1.55 $1.55  Exercised - - -  Forfeited (21,111) $1.74 - $99.00 $30.82  Outstanding, June 30, 2016 686,383 $1.45 - $116.40 $8.66        A summary of the restricted stock unit activity for the six month period ended June 3 0 , 201 6 is as follows:    Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2015 752,008 $2.63  Granted 791,600 $0.84  Vested (274,850) $2.56  Forfeited (56,262) $1.49  Outstanding, June 30, 2016 1,212,496 $1.53 

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	11. Fair Value Measurements  The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.  Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.  Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.  The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.       Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Assets at June 30, 2016:  Cash equivalents $ 74,346 74,346 — —  Total assets at fair value $ 74,346 74,346 — —  Liabilities at June 30, 2016:  Warrants issued May 2012 $ 209,156 — — 209,156  Warrants issued August 2013 $ 418,310 — — 418,310  Total liabilities at fair value: $ 627,466 — — 627,466  Assets at December 31, 2015:  Cash equivalents $ 524,083 524,083 — —  Total assets at fair value $ 524,083 524,083 — —  Liabilities at December 31, 2015:  Warrants issued May 2012 $ 143,681 — — 143,681  Warrants issued August 2013 $ 650,449 — — 650,449  Total liabilities at fair value: $ 794,130 — — 794,130  Level 1 The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $74,346 and $524,083 at June 30, 2016 and December 31, 2015 , respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the six month periods ended June 3 0 , 201 6 , and June 30 , 201 5 . There were no transfers in or out of Level 1 during the period ended June 3 0 , 2016. Level 2 The Company does not have any financial assets or liabilities classified as Level 2. Level 3 In conjunction with the Company’s May 2012 and August 2013 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements, the warrants did not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other expense” in the Statements of Operations. The remaining warrants from the May 2012 transaction expire in May 2018 and were revalued as of June 3 0 , 2016 using the following assumptions: 1) volatility of 124.33% ; 2 ) risk-free interest rate of 0.58% ; and 3) a closing stock price of $0.98 . The remaining warrants from the August 2013 expire in November 2018 a nd were revalued as of June 3 0 , 2016 using the following assumptions: 1 ) volatility of 113.17% ; 2) risk-free interest rate of 0.58% ; and 3) a closing stock price of $0.98 . The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in significantly higher (lower) liability fair value measurements.  The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the six month period ended June 3 0, 2016 :      Warrants issued May 2012 Warrants issued August 2013 Total Liabilities  Balance at beginning of period $ 143,681 $ 650,449 $ 794,130  Issues - - -  Settlements - - -  Revaluation 65,475 (232,139) (166,664)  Balance at end of period $ 209,156 $ 418,310 $ 627,466  The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

Product Warranty Provisions

Product Warranty Provisions	6 Months Ended
	Jun. 30, 2016
Product Warranty Provisions [Abstract]
Product Warranty Provisions	12. Product Warranty Provisions  The Company’s standard policy is to warrant all Niobe , Odyssey, and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.  Accrued warranty, which is included in other accrued liabilities, consists of the following:     June 30, 2016 December 31, 2015  Warranty accrual, beginning of the fiscal period $ 316,835 $ 364,548  Accrual adjustment for product warranty 48,064 171,384  Payments made (106,449) (219,097)  Warranty accrual, end of the fiscal period $ 258,450 $ 316,835 

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13. Commitments and Contingencies  The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On August 2, 2016, Stereotaxis, Inc. (the “Company”) received a determination letter from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that its common stock would be delisted from The Nasdaq Capital Market (“Nasdaq”) and that suspension of trading in the shares would be effective at the open of business on August 4, 2016. The determination letter also indicated that Nasdaq would complete the delisting by filing a Form 25 Notification of Delisting with the Securities Exchange Commission, after applicab le appeal periods have lapsed. The Panel made the determination to delist the Company’s common stock because the Company did not demonstrate compliance with the minimum $35 million market value of listed securities requirement for a period of ten consecutive trading days by August 1, 2016, as required by a decision previously issued by the Panel on May 2, 2016. The Company’s shares of common stock commenced trading on the OTCQX® Best Market on August 4, 2016 under the Company’s current ticker symbol of “STXS.” In August 2016, the Company entered into a sublease agreement to sublease approximately 27,000 square feet of office space through December 31, 2018 .     

Summary Of Significant Accoun20

Summary Of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the six month period ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016 or for future operating periods. These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission (SEC) on March 11, 2016.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Share-Based Compensation	Share-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests. The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.
Net Earnings (Loss) Per Common Share ("EPS")	Net Earnings (Loss) per Common Share (“EPS”) Basic and diluted net earnings (loss) per common share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. The following table sets forth the computation of basic and diluted EPS:    Three months ended June 30, Six months ended June 30,  Numerator: 2016 2015 2016 2015  Numerator for basic EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Numerator for diluted EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Denominator:  Denominator for basic EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Denominator for diluted EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Basic EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22)  Diluted EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22)  In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.  As of June 30, 2016, the Company had 686,383 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.66 per share, 2,040,365 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.44 per share, and 1,212,496 shares of unvested restricted share units.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company is evaluating the impact of this guidance on its financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842)”, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We adopted this accounting standard update in 2015 and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have adopted this accounting standard update. The Company’s balance sheets as of June 30, 2016 and December 31, 2015 included $291,060 and $349,018 , respectively, of deferred financing costs (excluding $75,068 and $25,960 , respectively, related to line-of-credit arrangements) that were, under the new guidance, presented as a direct reduction to debt liabilities. In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists and when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We are currently evaluating the impact of adopting this accounting standard update on our financial statement disclosures. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. In April 2015, the FASB issued an exposure draft related to the deferral of the effective date, which would delay our effective date one year. Therefore, the standard would be effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). We are currently evaluating the impact of adopting this accounting standard update on our financial statements and disclosures and have not concluded on an adoption method.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Computation Of Basic And Diluted EPS	  Three months ended June 30, Six months ended June 30,  Numerator: 2016 2015 2016 2015  Numerator for basic EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Numerator for diluted EPS $ (2,333,116) $ (1,538,687) $ (4,607,417) $ (4,674,268)  Denominator:  Denominator for basic EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Denominator for diluted EPS—weighted average shares 21,793,583 21,007,103 21,702,597 20,871,244  Basic EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22)  Diluted EPS $ (0.11) $ (0.07) $ (0.21) $ (0.22) 

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2016
Inventories [Abstract]
Schedule Of Inventories	  June 30, 2016 December 31, 2015   Raw materials $ 2,476,263 $ 2,065,676  Work in process 876,105 24,758  Finished goods 2,014,872 2,433,819  Reserve for obsolescence (32,553) (19,971)  Total inventory $ 5,334,687 $ 4,504,282 

Prepaid Expenses And Other Cu23

Prepaid Expenses And Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Prepaid Expenses And Other Current Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   June 30, 2016 December 31, 2015   Prepaid expenses $ 293,484 $ 454,822  Deferred financing costs 75,068 25,960  Deposits 245,650 136,583  Deferred cost of revenue 397 82,987  Total prepaid expenses and other assets 614,599 700,352  Less: Noncurrent prepaid expenses and other assets (44,774) (31,693)  Total current prepaid expenses and other assets $ 569,825 $ 668,659 

Property And Equipment (Tables)

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Property And Equipment [Abstract]
Schedule Of Property And Equipment	  June 30, December 31,  2016 2015   Equipment $ 8,386,835 $ 8,496,636  Equipment held for lease 303,412 303,412  Leasehold improvements 2,320,368 2,320,368  11,010,615 11,120,416  Less: Accumulated depreciation (10,152,746) (10,053,095)  Net property and equipment $ 857,869 $ 1,067,321 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  June 30, December 31,  2016 2015   Accrued salaries, bonus, and benefits $ 2,652,318 $ 3,053,012  Accrued rent 1,159,038 1,361,379  Accrued licenses and maintenance fees 575,583 666,373  Accrued interest 494,067 494,703  Accrued warranties 258,450 316,835  Accrued taxes 313,379 324,226  Other 248,516 117,465  Total accrued liabilities 5,701,351 6,333,993  Less: Long term accrued liabilities (270,296) (275,603)  Total current accrued liabilities $ 5,431,055 $ 6,058,390 

Deferred Revenue (Tables)

Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2016
Deferred Revenue [Abstract]
Schedule Of Deferred Revenue	  June 30, December 31,  2016 2015   Product shipped, revenue deferred $ 338,831 $ 366,388  Customer deposits 1,050,000 2,505,000  Deferred service and license fees 6,668,089 6,583,745  Total deferred revenue 8,056,920 9,455,133  Less: Long-term deferred revenue (620,945) (2,009,198)  Total current deferred revenue $ 7,435,975 $ 7,445,935 

Long-Term Debt And Credit Fac27

Long-Term Debt And Credit Facilities (Tables)	6 Months Ended
	Jun. 30, 2016
Long-Term Debt And Credit Facilities [Abstract]
Schedule Of Debt Outstanding	  June 30, 2016 December 31, 2015  Carrying Estimated Carrying Estimated  Amount Fair Value Amount Fair Value   Revolving line of credit, due March 31, 2018 $ 3,000,000 $ 3,000,000 $ - $ -  Healthcare Royalty Partners debt 18,114,408 18,405,468 18,080,159 18,429,177  Total debt 21,114,408 21,405,468 18,080,159 18,429,177  Less current maturities (3,000,000) (3,000,000) — —  Total long term debt $ 18,114,408 $ 18,405,468 $ 18,080,159 $ 18,429,177 

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Stockholders' Equity [Abstract]
Summary Of Option And Stock Appreciation Rights Activity	  Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share   Outstanding, December 31, 2015 706,494 $1.45 - $116.40 $9.34  Granted 1,000 $1.55 $1.55  Exercised - - -  Forfeited (21,111) $1.74 - $99.00 $30.82  Outstanding, June 30, 2016 686,383 $1.45 - $116.40 $8.66 
Summary Of Restricted Stock Unit Activity	  Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit   Outstanding, December 31, 2015 752,008 $2.63  Granted 791,600 $0.84  Vested (274,850) $2.56  Forfeited (56,262) $1.49  Outstanding, June 30, 2016 1,212,496 $1.53 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Measurements [Abstract]
Assets And Liabilities Measured At Fair Value On Recurring Basis By Level	  Fair Value Measurement Using  Total Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  Assets at June 30, 2016:  Cash equivalents $ 74,346 74,346 — —  Total assets at fair value $ 74,346 74,346 — —  Liabilities at June 30, 2016:  Warrants issued May 2012 $ 209,156 — — 209,156  Warrants issued August 2013 $ 418,310 — — 418,310  Total liabilities at fair value: $ 627,466 — — 627,466  Assets at December 31, 2015:  Cash equivalents $ 524,083 524,083 — —  Total assets at fair value $ 524,083 524,083 — —  Liabilities at December 31, 2015:  Warrants issued May 2012 $ 143,681 — — 143,681  Warrants issued August 2013 $ 650,449 — — 650,449  Total liabilities at fair value: $ 794,130 — — 794,130 
Summary Of Changes In Fair Value Of Level 3 Financial Liabilities	  Warrants issued May 2012 Warrants issued August 2013 Total Liabilities  Balance at beginning of period $ 143,681 $ 650,449 $ 794,130  Issues - - -  Settlements - - -  Revaluation 65,475 (232,139) (166,664)  Balance at end of period $ 209,156 $ 418,310 $ 627,466 

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	6 Months Ended
	Jun. 30, 2016
Product Warranty Provisions [Abstract]
Schedule Of Accrued Warranty	  June 30, 2016 December 31, 2015  Warranty accrual, beginning of the fiscal period $ 316,835 $ 364,548  Accrual adjustment for product warranty 48,064 171,384  Payments made (106,449) (219,097)  Warranty accrual, end of the fiscal period $ 258,450 $ 316,835 

Description Of Business (Detail

Description Of Business (Details)	Jun. 30, 2016USD ($)item	Dec. 31, 2015USD ($)
Description Of Business [Abstract]
Installed base | item	129
Cumulative net losses | $	$ (470,566,095)	$ (465,958,678)

Summary Of Significant Accoun32

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred financing costs	$ 291,060	$ 349,018
Deferred financing costs related to line-of-credit arrangements	$ 75,068	$ 25,960
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	4 years
Options and stock appreciation rights outstanding	686,383	706,494
Weighted average exercise price	$ 8.66	$ 9.34
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise of outstanding warrants	2,040,365
Exercise price of warrants	$ 3.44
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	1,212,496	752,008

Summary Of Significant Accoun33

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted EPS) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies [Abstract]
Numerator for basic EPS	$ (2,333,116)	$ (1,538,687)	$ (4,607,417)	$ (4,674,268)
Numerator for diluted EPS	$ (2,333,116)	$ (1,538,687)	$ (4,607,417)	$ (4,674,268)
Denominator for basic EPS-weighted average shares	21,793,583	21,007,103	21,702,597	20,871,244
Denominator for diluted EPS-weighted average shares	21,793,583	21,007,103	21,702,597	20,871,244
Basic EPS	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.22)
Diluted EPS	$ (0.11)	$ (0.07)	$ (0.21)	$ (0.22)

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 2,476,263	$ 2,065,676
Work in process	876,105	24,758
Finished goods	2,014,872	2,433,819
Reserve for obsolescence	(32,553)	(19,971)
Total inventory	$ 5,334,687	$ 4,504,282

Prepaid Expenses And Other Cu35

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 293,484	$ 454,822
Deferred financing costs	75,068	25,960
Deposits	245,650	136,583
Deferred cost of revenue	397	82,987
Total prepaid expenses and other assets	614,599	700,352
Less: Noncurrent prepaid expenses and other assets	(44,774)	(31,693)
Total current prepaid expenses and other assets	$ 569,825	$ 668,659

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 11,010,615	$ 11,120,416
Less: Accumulated depreciation	(10,152,746)	(10,053,095)
Net property and equipment	857,869	1,067,321
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,386,835	8,496,636
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,320,368	$ 2,320,368

Intangible Assets (Details)

Intangible Assets (Details)	Jun. 30, 2016USD ($)
Intangible Assets [Abstract]
Total intangible assets	$ 3,221,069
Accumulated amortization	$ 2,684,840

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Details)	3 Months Ended	6 Months Ended
	Sep. 30, 2013USD ($)ft²	Jun. 30, 2016USD ($)ft²	Dec. 31, 2015ft²
Office [Member]
Real Estate [Line Items]
Square feet of leased space		52,000	3,152
Sublease expiration date		Dec. 31, 2018
Demonstration And Assembly [Member]
Real Estate [Line Items]
Square feet of leased space		12,000
Unimproved [Member]
Real Estate [Line Items]
Square feet of leased space	13,000
Accrued lease termination costs | $	$ 515,138
Accrued lease termination costs remaining | $		$ 233,197

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,652,318	$ 3,053,012
Accrued rent	1,159,038	1,361,379
Accrued licenses and maintenance fees	575,583	666,373
Accrued interest	494,067	494,703
Accrued warranties	258,450	316,835	$ 364,548
Accrued taxes	313,379	324,226
Other	248,516	117,465
Total accrued liabilities	5,701,351	6,333,993
Less: Long term accrued liabilities	(270,296)	(275,603)
Total current accrued liabilities	$ 5,431,055	$ 6,058,390

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 8,056,920	$ 9,455,133
Less: Long-term deferred revenue	(620,945)	(2,009,198)
Total current deferred revenue	7,435,975	7,445,935
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	338,831	366,388
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	1,050,000	2,505,000
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 6,668,089	$ 6,583,745

Long-Term Debt And Credit Fac41

Long-Term Debt And Credit Facilities (Narrative) (Details)	Jan. 31, 2013USD ($)	Aug. 08, 2012USD ($)	Nov. 30, 2011USD ($)	Jun. 30, 2016USD ($)	May 10, 2016USD ($)	Dec. 31, 2015USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Cash and cash equivalents				$ 3,858,089		$ 5,593,582	$ 3,629,273	$ 7,270,301
Term Loan [Member] | Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount borrowed	$ 2,500,000	$ 2,500,000	$ 15,000,000
Additional amount which may be borrowed			$ 5,000,000
Percentage of royalties entitled to receive			100.00%
Maturity date				Dec. 31, 2018
Annual interest rate			16.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 10,000,000
Line of credit facility, maturity date				Mar. 31, 2018
Minimum tangible net worth requirement, period one					$ (24,000,000)
Minimum tangible net worth requirement, period two					$ (24,500,000)
Line of credit facility, amount outstanding				$ 3,000,000
Line of credit facility, current borrowing capacity				4,000,000
Line of credit facility, additional borrowings available				1,000,000
Total liquidity				4,900,000
Line of credit facility, repayments				$ 3,000,000
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Liquidity ratio					1.50

Long-Term Debt And Credit Fac42

Long-Term Debt And Credit Facilities (Schedule Of Debt Outstanding) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Less current maturities	$ (3,000,000)
Total long term debt	18,114,408	$ 18,080,159
Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt	21,114,408	18,080,159
Less current maturities	(3,000,000)
Total long term debt	18,114,408	18,080,159
Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt	21,405,468	18,429,177
Less current maturities	(3,000,000)
Total long term debt	$ 18,405,468	18,429,177
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maturity date	Mar. 31, 2018
Revolving Credit Facility [Member] | Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt	$ 3,000,000
Revolving Credit Facility [Member] | Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt	3,000,000
Healthcare Royalty Partners Debt [Member] | Term Loan [Member] | Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt	18,114,408	18,080,159
Healthcare Royalty Partners Debt [Member] | Term Loan [Member] | Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt	$ 18,405,468	$ 18,429,177

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	May 24, 2016shares	Jun. 10, 2014shares	Jun. 05, 2013shares	May 31, 2014USD ($)	Jun. 30, 2016USD ($)shares	Jun. 30, 2016USD ($)itemshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Votes per share | item						1
Dividends declared					$ 0	$ 0
Dividends paid						$ 0
Increase in number of shares authorized for issuance under the Plan | shares	1,500,000	1,000,000	1,000,000
Stock award plans | shares					1,508,565	1,508,565
Total compensation cost not yet recognized					$ 1,900,000	$ 1,900,000
Estimated forfeitures						$ 900,000
Weighted average amortization period of total compensation cost not yet recognized						4 years
Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross sales price				$ 18,000,000
Commission percentage of gross proceeds				3.00%
Gross proceeds from common stock sold					0
Remaining common stock available					$ 13,800,000	$ 13,800,000
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares exercised upon conversion of warrants | shares						267,256
Gross proceeds from stock warrants exercised						$ 293,982

Stockholders' Equity (Summary O

Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2015	706,494
Number of Options/SARs, Granted	1,000
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(21,111)
Number of Options/SARs, Outstanding, June 30, 2016	686,383	706,494
Weighted Average Exercise Price per Share, Outstanding, December 31, 2015	$ 9.34
Weighted Average Exercise Price per Share, Granted	1.55
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	30.82
Weighted Average Exercise Price per Share, Outstanding, June 30, 2016	8.66	$ 9.34
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit		1.45
Range of Exercise Price, Upper Limit		$ 116.40
$1.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Upper Limit	1.55
$1.74 - $99.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	1.74
Range of Exercise Price, Upper Limit	99
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	1.45
Range of Exercise Price, Upper Limit	$ 116.40

Stockholders' Equity (Summary45

Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2015 | shares	752,008
Number of Restricted Stock Units, Granted | shares	791,600
Number of Restricted Stock Units, Vested | shares	(274,850)
Number of Restricted Stock Units, Forfeited | shares	(56,262)
Number of Restricted Stock Units, Outstanding, June 30, 2016 | shares	1,212,496
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2015 | $ / shares	$ 2.63
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	0.84
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	2.56
Weighted Average Grant Date Fair Value per Unit, Forfeited | $ / shares	1.49
Weighted Average Grant Date Fair Value per Unit, Outstanding, June 30, 2016 | $ / shares	$ 1.53

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 74,346	$ 524,083
Financial assets	74,346	524,083
Financial liabilities	627,466	794,130
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	74,346	524,083
Transfers into Level 1	0
Transfers out of Level 1	0
Financial assets	74,346	524,083
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 627,466	$ 794,130
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	May 1, 2018
Volatility rate	124.33%
Risk-free interest rate	0.58%
Closing stock price	$ 0.98
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date	Nov. 1, 2018
Volatility rate	113.17%
Risk-free interest rate	0.58%
Closing stock price	$ 0.98

Fair Value Measurements (Assets

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 74,346	$ 524,083
Total assets at fair value	74,346	524,083
Warrants issued	627,466	794,130
Total liabilities at fair value	627,466	794,130
Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	209,156	143,681
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	418,310	650,449
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	74,346	524,083
Total assets at fair value	74,346	524,083
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	627,466	794,130
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	209,156	143,681
Significant Unobservable Inputs (Level 3) [Member] | Recurring [Member] | Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 418,310	$ 650,449

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 794,130
Issues
Settlements
Revaluation	(166,664)
Balance at end of period	627,466
Warrants Issued May 2012 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	143,681
Issues
Settlements
Revaluation	65,475
Balance at end of period	209,156
Warrants Issued August 2013 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	650,449
Issues
Settlements
Revaluation	(232,139)
Balance at end of period	$ 418,310

Product Warranty Provisions (De

Product Warranty Provisions (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Product Warranty Provisions [Abstract]
Standard product warranty coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 316,835	$ 364,548
Accrual adjustment for product warranty	48,064	171,384
Payments made	(106,449)	(219,097)
Warranty accrual, end of the fiscal period	$ 258,450	$ 316,835

Subsequent Events (Details)

Subsequent Events (Details) - Office [Member] - ft²	6 Months Ended
	Jun. 30, 2016	Aug. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Square feet of leased space	52,000		3,152
Sublease expiration date	Dec. 31, 2018
Subsequent Event [Member]
Subsequent Event [Line Items]
Square feet of leased space		27,000